Read our latest updates & insights

On 3 February 2026, Bio-Thera Solutions and Saudi-based Avalon Pharma announced that they have entered commercialisation and licence agreements for Bio-Thera’s BAT3306, biosimilar to MSD’s Keytruda® (pembrolizumab), in Saudi Arabia and MENA.

Under the agreement, Aval...

On 3 February 2026, Amgen announced its financial results for Q4/2025 and full year 2025, including providing the following update on its biosimilar pipeline:

Nivolumab: Amgen has completed enrolment in a comparative clinical study comparing ABP 206 (nivolumab) wit...

On 2 February 2026, Alvotech announced that it has entered into supply and commercialisation agreements with Sandoz for multiple unidentified biosimilars for Australia, New Zealand and Canada.

In Australia and New Zealand, the agreement covers three biosimilars acros...

On 2 February 2026, R-Pharm announced that the Russian Ministry of Health has approved Persinthia™, biosimilar to Genentech/Roche’s Perjeta® (pertuzumab), for the treatment of HER2-positive breast cancer.  The approval follows R-Pharm’s announcement in December 2025 at the ...

On 2 February 2026, Sandoz announced that it has launched Enzeevu®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2mg, in Canada.  Enzeevu® was approved by Health Canada in October 2025 for all Eylea® indications.

Other aflibercept biosimilars approved in Cana...

On 1 February 2026, Sandoz’s Afqlir®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2mg, was listed on Australia’s Pharmaceutical Benefits Scheme (PBS) in vial and pre-filled syringe presentations for all reference indications.  Afqlir® is Australia’s first afliberce...

On 30 January 2026, Celltrion announced that it has launched Avtozma®, biosimilar to Roche’s Actemra® (tocilizumab), in major European countries, including Germany, France and Spain.

Celltrion’s launch strategy in France has involved winning bids from private hospita...

At its December 2025 Intracycle Meeting (the outcomes of which were published on 30 January 2026), the Australian Pharmaceutical Benefits Advisory Committee (PBAC) recommended a broad, multi-indication PBS listing of MSD’s Keytruda® (pembrolizumab) for the treatment of adva...

On 30 January 2026, Samsung Bioepis announced that it has secured a settlement and licence agreement with Regeneron and Bayer for the commercialisation of SB15, biosimilar to Eylea® (aflibercept, 2 mg), in countries excluding the US and Canada.  The announcement comes a day...